This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Christian Onyebuchi Ifediora | |
---|---|
Born | Enugu State, Nigeria |
Citizenship | Nigeria |
Alma mater | Harvard University University of Liverpool Nnamdi Azikiwe University University of Southern Queensland Griffith University |
Known for | The OCI Foundation, Founder, OCI Foundation International |
Spouse | Nkem Eucharia Ifediora |
Children | 4 |
Scientific career | |
Fields | Medical practitioner |
Institutions | Griffith University |
Christian Onyebuchi Ifediora is a Nigerian medical practitioner and educator. [1] He is currently an associate professor at Griffith University. [2] He founded the Onyebuchi Chris Ifediora (OCI) Foundation, an international non-profit organization. [3] [4]
Christian Onyebuchi Ifediora was born in Enugu, Enugu State, Nigeria. He is from Nsugbe [5] [6] [7] in Anambra State. In 2004, he obtained his MBBS from Nnamdi Azikiwe University. [8] He completed a master's in public health (MPH) from the University of Liverpool in 2008. [9] In 2019, he received the Southeast Asia Leadership (HMS-SEAL) qualification from Harvard Medical School and is currently pursuing a Ph.D. at the University of Southern Queensland. [7]
In 2005, Ifediora worked as a house officer at the Lagos University Teaching Hospital, Lagos, Nigeria. [10]
In 2006, he served as a medical officer at General Hospital, Irepo Local Government Area, Oyo State, Nigeria, as part of his National Youth Service Corps (NYSC) assignment, receiving a meritorious service award from Oyo State. [11] [12] [13]
During his MPH program in 2008, Ifediora had a clinical attachment at the Royal Liverpool and Broadgreen University Teaching Hospital in the UK. After his MPH, he worked in various surgical specialities and emergency departments in the UK before relocating to Australia in late 2008. He joined the Royal Hobart Hospital as a resident medical officer. [14] [15]
In 2010, Ifediora established the Cyfed Medical Group. [16] He practices as a family physician in the City of Gold Coast, Australia, and earned a Fellowship from the Royal Australian College of General Practitioners (FRACGP) in 2013. He joined Griffith University School of Medicine as a senior lecturer in clinical skills, becoming an associate professor in 2019. [17]
Ifediora has contributed to medical education as a fellowship examiner, supervisor, and general practice educator. He has also served on the Monitored Substances Schedule Working Party for the State of Queensland, developing a real-time monitoring tool for opioid prescriptions. [18]
In 2016, Ifediora founded the Onyebuchi Chris Ifediora (OCI) Foundation, which was registered internationally in 2018. Through the foundation, he leads the Arm Our Youths (ArOY) Health Campaign, promoting anti-breast and anti-cervical cancer messages to young adults in Nigeria. [19] The campaign is integrated into the curriculum of multiple Nigerian schools and NYSC camps, with plans for expansion across Africa. He also designed the OCI CerviBreast App, which provides information on breast and cervical cancer. [20]
Ifediora has been featured in various Nigerian and Australian media outlets. He has been involved with several professional organizations, including the RACGP Queensland Research Support and Education Committees and the Monitored Substances Schedule Working Party. [21] [22] [23]
Ifediora is married to Nkem Ifediora, and they have four children. [24] [25]
Ifediora and the OCI Foundation have received numerous awards from organizations such as Rotary International and the Nigerian Bar Association. In October 2024, Ifediora was announced winner of the "People's Choice Award" for the Three Minute Thesis (3MT) competition of doctoral students at the University of Southern Queensland, Australia. [26] He holds the traditional title of Chizitelu (God Sent) the 1st of Nigeria and Africa [27] [28]
The Papanicolaou test is a method of cervical screening used to detect potentially precancerous and cancerous processes in the cervix or, more rarely, anus. Abnormal findings are often followed up by more sensitive diagnostic procedures and, if warranted, interventions that aim to prevent progression to cervical cancer. The test was independently invented in the 1920s by the Greek physician Georgios Papanikolaou and named after him. A simplified version of the test was introduced by the Canadian obstetrician Anna Marion Hilliard in 1957.
Cervical cancer is a cancer arising from the cervix or in any layer of the wall of the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal vaginal bleeding, pelvic pain or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.
Cancer staging is the process of determining the extent to which a cancer has grown and spread. A number from I to IV is assigned, with I being an isolated cancer and IV being a cancer that has metastasized and spread from its origin. The stage generally takes into account the size of a tumor, whether it has invaded adjacent organs, how many regional (nearby) lymph nodes it has spread to, and whether it has appeared in more distant locations (metastasized).
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
A papilloma is a benign epithelial tumor growing exophytically in nipple-like and often finger-like fronds. In this context, papilla refers to the projection created by the tumor, not a tumor on an already existing papilla.
The Union for International Cancer Control or UICC is a non-governmental organisation with over 1,150 member organisations in more than 170 countries and territories.
Human papillomavirus (HPV) vaccines are vaccines intended to provide acquired immunity against infection by certain types of human papillomavirus (HPV). The first HPV vaccine became available in 2006. Currently there are six licensed HPV vaccines: three bivalent, two quadrivalent, and one nonavalent vaccine All have excellent safety profiles and are highly efficacious, or have met immunobridging standards. All of them protect against HPV types 16 and 18, which are together responsible for approximately 70% of cervical cancer cases globally. The quadrivalent vaccines provide additional protection against HPV types 6 and 11. The nonavalent provides additional protection against HPV types 31, 33, 45, 52 and 58. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% effectiveness in preventing HPV-positive oropharyngeal cancers. They also protect against penile cancer. They additionally prevent genital warts, with the quadrivalent and nonavalent vaccines providing virtually complete protection. The WHO recommends a one or two-dose schedule for girls aged 9–14 years, the same for girls and women aged 15–20 years, and two doses with a 6-month interval for women older than 21 years. The vaccines provide protection for at least five to ten years.
Gardasil is an HPV vaccine for use in the prevention of certain strains of human papillomavirus (HPV). It was developed by Merck & Co. High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. The HPV strains that Gardasil protects against are sexually transmitted, specifically HPV types 6, 11, 16 and 18. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal, vulvar, vaginal, and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. HPV type 16 is responsible for almost 90% of HPV-positive oropharyngeal cancers, and the prevalence is higher in males than females. Though Gardasil does not treat existing infection, vaccination is still recommended for HPV-positive individuals, as it may protect against one or more different strains of the disease.
Nsugbe is a town in Anambra East Local Government Area, Anambra State, Nigeria.It is a suburb of Onitsha.
Healthcare in Nigeria is a concurrent responsibility of the three tiers of government in the country. Private providers of healthcare have a visible role to play in healthcare delivery. The use of traditional medicine (TM) and complementary and alternative medicine (CAM) has increased significantly over the past few years.
Healthcare in Ghana is mostly provided by the national government, and less than 5% of GDP is spent on healthcare. The healthcare system still has challenges with access, especially in rural areas not near hospitals.
The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.
Worldwide, breast cancer is the most common invasive cancer in women. Breast cancer comprises 22.9% of invasive cancers in women and 16% of all female cancers.
Project Pink Blue, registered as Health & Psychological Trust Centre is a cancer nonprofit engaged in raising cancer awareness, patient navigation, advocacy and free breast and cervical cancer screening for women living in poverty. The organization launched Nigeria's first patient navigation in 2015 and a toll- free telephone centre 08000CANCER in 2016 Project PINK BLUE won the SPARC Metastatic Breast Cancer challenge grant by Union for International Cancer Control and Pfizer Oncology in Lisbon, Portugal.
Princess Dina Mired is a Jordanian global health advocate particularly in the field of cancer control and non-communicable diseases (NCDs). She was the President of the Union for International Cancer Control (UICC) from 2018 to 2020, and is the former Director-General of the King Hussein Cancer Foundation
Melissa Andrea Simon is an American clinical obstetrician/gynecologist and scientist who focuses on health equity across the lifespan. Simon is founder and director of the Center for Health Equity Transformation (CHET) in the Feinberg School of Medicine at Northwestern University in Chicago, Illinois, and founder of the Chicago Cancer Health Equity Collaborative, a National Cancer Institute comprehensive cancer partnership led by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northeastern Illinois University, and the University of Illinois at Chicago. She is the George H. Gardner, MD Professor of Clinical Gynecology, the Vice-Chair of Clinical Research in the Department of Obstetrics and Gynecology, tenured professor of Obstetrics and Gynecology, Preventive Medicine and Medical Social Sciences at Northwestern University Feinberg School of Medicine, and Associate Director of Community Outreach and Engagement at the Robert H. Lurie Comprehensive Cancer Center.
Mgbakogu Robinson Amaechi is a Nigerian academic. who has served as the provost of Anambra State College of Health Technology, Obosi, Anambra State, Nigeria since 2013.
Karen Canfell is an Australian epidemiologist and cancer researcher.
Current estimates indicates that over 24,000 new cases of cancer are recorded each year at Ghana. In 2020, 15,802 Ghanaians died from cancer. Nearly 95,000 cases of cancer were reported in Ghana in 2019. A 2015 study in Kumasi recorded breast and cervical cancer raked high records among females. Prostate cancer recorded the highest among males. Breast, liver and cervical were leading in both sexes.
Zainab Shinkafi Bagudu is a global cancer advocate with interest in women's health, Founder of MedicAid Cancer Foundation, she advocates for cancer awareness by providing training for healthcare workers, supports the screening, diagnosis and treatment of cancer patients in Nigeria. She is a contributor/columnist at Blueprint Newspaper She is also consultant pediatrician.